Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Harvard Business School
Merck
Moodys

Last Updated: May 24, 2022

Meloxicam - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for meloxicam and what is the scope of patent protection?

Meloxicam is the generic ingredient in five branded drugs marketed by Lupin Ltd, Novitium Pharma, Iceutica Operations, Baudax, Avondale Pharms, Tersera, Aiping Pharm Inc, Anda Repository, Apotex Inc, Aurobindo Pharma, Cipla, Cr Double Crane, Dr Reddys Labs Inc, Glenmark Generics, Heritage Pharma, Impax Labs Inc, Lupin Pharms, Mylan, Puracap Pharm, Roxane, Strides Pharma, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, and Boehringer Ingelheim, and is included in twenty-nine NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has sixty-four patent family members in twenty-three countries.

There are twenty-two drug master file entries for meloxicam. Forty-one suppliers are listed for this compound.

Drug Prices for meloxicam

See drug prices for meloxicam

Drug Sales Revenue Trends for meloxicam

See drug sales revenues for meloxicam

Recent Clinical Trials for meloxicam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MiamiPhase 3
Mayo ClinicPhase 4
Alfarabi CollegesN/A

See all meloxicam clinical trials

Pharmacology for meloxicam
Paragraph IV (Patent) Challenges for MELOXICAM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIVLODEX Capsules meloxicam 5 mg and 10 mg 207233 1 2017-01-09
MOBIC Oral Suspension meloxicam 7.5 mg/5 mL 021530 1 2009-12-17

US Patents and Regulatory Information for meloxicam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan MELOXICAM meloxicam TABLET;ORAL 077923-002 Jul 19, 2006 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Avondale Pharms MOBIC meloxicam SUSPENSION;ORAL 021530-001 Jun 1, 2004 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tersera QMIIZ ODT meloxicam TABLET, ORALLY DISINTEGRATING;ORAL 211210-002 Oct 19, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Roxane MELOXICAM meloxicam TABLET;ORAL 077925-002 Jul 19, 2006 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Iceutica Operations VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for meloxicam

Country Patent Number Title Estimated Expiration
Japan 6072539 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2010138539 See Plans and Pricing
Japan 4891774 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2005002542 See Plans and Pricing
Morocco 39443 Nouvelle formulation de méloxicam See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Express Scripts
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.